Levonorgestrel API Market

Levonorgestrel API Market Size was valued at USD 52.01 Mn in 2023 and is predicted to reach USD 71.37 Mn by 2031 at a 4.13% CAGR during the forecast period for 2024-2031.

Levonorgestrel is a medicine that is mostly prescribed for the purpose of preventing pregnancy. There are many ways to actively use this hormone drug to control birth. If all other methods of preventing pregnancy have been exhausted, an emergency contraceptive may be utilized. It stops eggs from follicular attachment as well. One of the best ways to prevent unwanted pregnancies is by using this strategy. The rise of chronic diseases, the need for more individualized treatments, and innovative drug delivery systems are just a few of the factors that experts predict will drive the active pharmaceutical component industry forward. The intrauterine system (IUS), which stands for levonorgestrel-releasing intrauterine system, is easily reversible. Additionally, it keeps working for a long time. The fact that it combines the benefits of hormonal and intrauterine contraception is a bonus to its already impressive efficiency. This has played a role in the growth of the levonorgestrel API industry.

However, the market growth is hampered by the high-cost criteria for the safety and health of the levonorgestrel API market and the product's inability to prevent fog in environments with dramatic temperature fluctuations or high levonorgestrel API because potential problems with intermittency and reliability are noticeable in certain Levonorgestrel API solutions, such as wind and solar power. They become more problematic in areas where weather patterns are unexpected. Levonorgestrel API solutions, especially for large-scale applications, need a big upfront expenditure, which is a major obstacle to industry expansion. The COVID-19 pandemic and the supply chain disruptions it caused, such as manufacturing closures and constraints, have caused sales of API commodities to decline.

Competitive Landscape

Some of the Major Key Players in the Levonorgestrel API Market are

Bayer HealthCare
Qinhuangdao Zizhu Pharmaceutical
Yangzhou Pharmaceutical
Lupin
Hubei Gedian Humanwell
Sterling Spa
Formos
Huazhong Pharm
ASG Biochem

Market Segmentation:

The levonorgestrel API market is segmented based on type and application. Based on type, the market is segmented into short-acting contraceptive API and long-acting contraceptive API. By application, the market is segmented into levonorgestrel tablets, mixture products, and hormone-releasing IUDs.

Based on the Type, the Short-Acting Contraceptive API Segment is Accounted as a Major Contributor to the Levonorgestrel API Market

The short-acting contraceptive API segment is expected to hold a major global market share in 2023. Short-acting contraceptives, such as oral contraceptive pills and injectables, are widely used methods of birth control due to their convenience and effectiveness. This high demand drives the need for levonorgestrel APIs, which are a key component in many of these contraceptive products. Levonorgestrel is a progestin hormone commonly used in various forms of contraceptives because of its efficacy in preventing pregnancy. Its effectiveness contributes to its widespread usage in short-acting contraceptives, further bolstering the demand for levonorgestrel APIs.

Hormone-Releasing IUD Segment to Witness Growth at a Rapid Rate

The hormone-releasing IUD industry makes up the bulk of acrylic acid ester usage because the hormone progesterone is produced naturally by the human body and is remarkably similar to progestin. While utilizing an intrauterine device (IUD), the hormones might alleviate heavy or painful periods in addition to preventing pregnancy, especially in countries like the US, Germany, the UK, China, and India.

In the Region, the North American Levonorgestrel API Market Holds a Significant Revenue Share

The North American levonorgestrel API market is expected to register the highest revenue share in the near future. This can be attributed to the robust system of medical care and the rising healthcare costs. In addition, Asia Pacific is projected to grow rapidly in the global Levonorgestrel API Market due to the increasing number of women in the population, the prevalence of strong and stringent policies for the payment of contraceptives, and the rates of fertility.

Recent Developments:

In January 2024, Bayer and Google Cloud announced their partnership to bring AI solutions to aid radiologists and, in the long run, patients. In order to speed up the creation and implementation of AI-powered healthcare apps, particularly in the field of radiology, Bayer will be utilizing Google Cloud's technology, particularly its generative AI (gen AI) capabilities, inside its innovation platform.

In March 2024, Lupin, a global pharmaceutical behemoth, announced the arrival of Oracea's first generic version—Doxycycline Capsules, 40 mg—in the US market after receiving clearance from the FDA.